Clin2
NCT06162650Likely a fitRecruiting

Pre-surgery chemo-radiation therapy for rectal cancer

Rectal Cancer

Treatments studied

Part of Cancer, Digestive system clinical trials.

This trial tests a combination of chemotherapy and radiation therapy before surgery for people with mid or low rectal cancer that hasn't spread. The goal is to see if this approach works better than current treatments.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
42 people
Ages
20 years and older
Study type
Interventional

Who can take part

  • You have been diagnosed with adenocarcinoma of the rectum (a type of rectal cancer).
  • Your tumor is located in the mid or lower rectum (less than 10 cm from the anus).
  • Your cancer is stage II or III, meaning it has not spread to other parts of the body.
  • You have not had any prior chemotherapy, radiation, or surgery for this rectal cancer.
  • You are at least 20 years old and in good enough health to handle treatment (ECOG score 0 or 1).
  • Your liver, kidney, and blood cell counts are within acceptable ranges, and you do not have active infections or serious heart problems.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT04643366Recruiting· Phase 2
Total treatment with chemotherapy and short radiation before surgery

This trial tests whether combining chemotherapy (mFOLFOX6) and a short course of radiation before surgery improves outcomes for people with resectable rectal cancer. The goal is to shrink and control the cancer early and then remove it with curative surgery.

Richmond, Virginia
NCT03975049Not yet recruiting· Phase 3
Checking the best pre-surgery treatment for rectal cancer

This Phase 3 trial compares different chemotherapy and radiation combinations given before surgery for locally advanced rectal cancer, to see which one works better. It may help people get a tumor removed completely (R0 resection) and improve outcomes while comparing treatment safety and effectiveness.

NCT06599827Not yet recruiting· Phase 2
Shorter radiation plus chemo and immunotherapy for high-risk rectal cancer

This trial tests a shorter course of radiation combined with chemotherapy and immunotherapy before surgery for high-risk rectal cancer. The goal is to see if this combination shrinks the tumor more effectively and improves outcomes.

Shanghai, Shanghai Municipality
NCT03466424Recruiting
Short radiation then chemotherapy for locally advanced rectal cancer

This trial tests a short course of radiation given before chemotherapy for people with locally advanced rectal cancer (cancer that has grown into nearby tissue and/or nearby lymph nodes but can still be removed). It may help shrink the tumor and make treatment more effective while assessing how well this approach works.

Fuzhou, Fujian
NCT05752136Recruiting· Phase 3
Pre-surgery radiation plus immunotherapy and chemo for rectal cancer

This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.

Hangzhou, Zhejiang
NCT06958432Recruiting· Phase 2/Phase 3
Short-course radiation plus chemo and immunotherapy for rectal cancer

This trial tests a treatment plan that uses a short course of radiation to the lymph nodes-sparing area, followed by chemotherapy and an immunotherapy drug (PD-1 inhibitor) for people with a specific type of mid or low rectal cancer (pMMR/MSS). The goal is to see if this approach can shrink the tumor and improve outcomes without needing extensive surgery.

Guangzhou, Guangdong

Hear when a new Rectal Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.